Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Buy the Dip: ExxonMobil Looks Cheap After Recent Oil Weakness
High free cash flow, rising production and a strong balance sheet make XOM a tactical long while crude corrects
Exxon Mobil (XOM) is an integrated oil major that has proven it can generate large free cash flow and return it to shareholders even in a soft oil-pri...
Chevron: Buy the Breakout — Strong Cash Flow, Dividend Tailwinds, and Reasonable Valuation
Actionable long trade on CVX after earnings-driven breakout; entry, stop, and two targets with risk framing.
Chevron just broke to fresh highs after 01/30/2026 results and a dividend raise. The company is generating robust operating cash flow, raising the pay...
Xeris Biopharma: Recorlev Driving a Tactical Long — Entry, Stops and Targets
Q3 operational turnaround, improving cash flow and a still-young revenue base create a high-reward swing trade
Xeris (XERS) has shown clear top-line momentum driven by Recorlev and improving unit economics. Q3 2025 delivered $74.4M in revenue and a small GAAP p...
Italian NOP Program Validates TransMedics' Global Scale Play — Trade the Next Leg Higher
Clinical adoption in Italy is the first tangible proof that normothermic organ perfusion can scale outside the U.S.; fundamentals and cash flow support a disciplined long with defined risk controls.
TransMedics is showing durable top-line growth, positive operating income and meaningful operating cash flow as it pushes Organ Care System adoption i...
Village Farms: From Salad Aisles to Cannabis Growth - A Tactical Long
Play selective upside in VFF as cannabis scale and greenhouse efficiencies re-rate the business; use tight risk controls given litigation and regulatory noise.
Village Farms (VFF) is a capital-light greenhouse operator whose produce business funds a growing, export-focused cannabis platform. Recent Q3 2025 re...
Salesforce: AI Adoption Is Accelerating — Revenue Lag Creates a Tactical Long
Agent-driven AI demand is real; the stock is pricing in risk. Trade idea: buy the recovery in execution while monitoring ARR conversion.
Salesforce is at the center of enterprise AI adoption — product uptake and customer deployments are accelerating, but revenue is still catching up. ...
Arbutus (ABUS) - Binary Near-Term Trade: Imdusiran Data + LNP Litigation Could Spark 50%-100% Upside
Clinical progress in imdusiran and an unresolved LNP litigation create a near-term asymmetric trade; balance the binary upside with a thin but real cash runway.
Arbutus Biopharma (ABUS) is a speculative long with defined risk/reward. Positive imdusiran data already reported and an outstanding LNP litigation (d...
JinkoSolar: A Swing-Trade for Income and Volatility — Play the Rebound, Respect the Policy Risk
Dividend yield and mid-cycle recovery set up upside into near-term resistance, but China policy and sector oversupply make this a high-risk trade
JinkoSolar (JKS) is trading around $25.86 with a recent cash dividend and a Q4 2025 revenue estimate of $2.89B. The stock sits roughly midway in a wid...
HP Inc. - Cycle-Low Long: Buy a High-Yield, Buyback-Supported Rebound
Near-term setup: buy the share-cannibal story at ~19; big yields, active financing outflows, and an upcoming earnings catalyst create an asymmetric trade.
HP is trading near 52-week lows (~$19.4) while returning capital aggressively via dividends and likely buybacks. Recent quarterly results show stable ...
Byrna (BYRN) - Tactical Long After a Sharp Pullback: Small Position, Defined Risk
Quality margins, clean balance sheet, and a run-rate near $110M — but inventory and cash flow make this a high-risk trade.
Byrna Technologies' recent ~25% pullback opens a high-risk, high-reward swing entry. The company is profitable on the quarter level (Q3 FY2025 net inc...
Halozyme: Acquisitions and Royalty Engines Position HALO for Multi-Year Growth — A Long Trade With Defined Risk
Recent M&A momentum plus expanding ENHANZE royalty streams create a constructive risk/reward for long-term investors; trade idea with entries, stops and targets.
Halozyme (HALO) has posted accelerating revenue and profit in 2025 while using acquisitions and licensing to build recurring royalty streams. Q3 FY202...
Berkshire Hathaway: Why I'm More Bullish Now — and How to Trade It
Strong cash generation, rising equity and heavy capital deployment make BRK.A a buy from current levels; here's an actionable entry, stops and targets.
Berkshire Hathaway is firing on multiple cylinders: Q3 2025 operating cash flow remains strong, book value keeps rising and management is actively dep...